SureTrader
Interactive Brokers Advertisement
Home > Boards > US Listed > Biotechs >

Bioverativ Inc. (BIVV)

BIVV RSS Feed
Add BIVV Price Alert      Hide Sticky   Hide Intro
Moderator:
Search This Board: 
Last Post: 7/26/2017 2:20:59 PM - Followers: 2 - Board type: Free - Posts Today: 0

About Bioverativ Bioverativ is a global biotechnology company dedicated to transforming the lives of people with hemophilia and other rare blood disorders through world-class research, development and commercialization of innovative therapies. Launched in 2017 following separation from Biogen Inc., Bioverativ builds upon a strong heritage of scientific innovation and is committed to actively working with the blood disorders community. The company’s mission is to create progress for patients where they need it most and its hemophilia therapies when launched represented the first major advancements in hemophilia treatment in more than two decades. For more information, visit www.bioverativ.com or follow @bioverativ on Twitter. Bioverativ Inc. MEDIA CONTACT: Tracy Vineis, +1 781-663-4350 media@bioverativ.com or INVESTOR CONTACT: Susan Altschuller, +1 781-663-4360 IR@bioverativ.com
SureTrader
Interactive Brokers Advertisement
BIVV
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
SureTrader
BIVV News: Bioverativ’s Investigational BIVV009 Demonstrates Safety, Tolerability & Efficacy in Phase 1b Clinical Trial in Cold Agglut... 02:47 PM
BIVV News: New Data Show Extended Prophylactic Dosing with ALPROLIX® Provides Safe & Effective Protection in People with Severe Hemophi... 10:02 AM
BIVV News: Study Shows Weekly Prophylactic Treatment with ELOCTATE® Resulted in Bleed Protection & Target Joint Resolution in People wi... 12/10/2017 09:02:00 AM
BIVV News: ALPROLIX® Demonstrates Higher Tissue Distribution & Retention in Joints Compared to Other Factor IX Molecules in a Preclinic... 12/09/2017 09:02:00 AM
BIVV News: U.S. Label Update for ALPROLIX® Adds Data Reinforcing Efficacy & Safety of Long-Term Prophylactic Treatment in Adults, Adol... 11/27/2017 07:30:00 AM
News News Alert: Bioverativ’s Investigational BIVV009 Demonstrates Safety, Tolerability & Efficacy in Phase 1b Clinical Trial in Cold Agglut... 12/11/2017 02:47:00 PM
PostSubject
#4   Thank you BIIB :-D Cbdpotential 07/26/17 02:20:59 PM
#3   Wow! Just keeps going up... $bivv Cbdpotential 04/28/17 09:47:07 AM
#2   HealthCor Management, L.P. has filed a new 13G, wiltonio 04/13/17 04:03:11 PM
#1   Long-term Safety and Efficacy Extension Study Data of Cbdpotential 04/05/17 10:27:46 AM
PostSubject